OTCMKTS:FSNUY Fresenius SE & Co. (FSNUY) Stock Price, News & Analysis $11.98 +0.02 (+0.17%) As of 08/1/2025 03:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesShort InterestBuy This Stock About Fresenius SE & Co. Stock (OTCMKTS:FSNUY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fresenius SE & Co. alerts:Sign Up Key Stats Today's Range$11.88▼$12.1250-Day Range$11.91▼$12.8552-Week Range$8.35▼$12.97Volume23,427 shsAverage Volume35,126 shsMarket CapitalizationN/AP/E Ratio63.06Dividend Yield1.59%Price TargetN/AConsensus RatingBuy Company Overview Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany. Read More Receive FSNUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fresenius SE & Co. and its competitors with MarketBeat's FREE daily newsletter. Email Address FSNUY Stock News HeadlinesStocks To Watch: Fresenius Medical Care Sees Relative Strength Rating Rise To 81July 24, 2025 | msn.comFresenius SE & Co. KGaA (FSNUY) - Yahoo FinanceJuly 20, 2025 | uk.finance.yahoo.comThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself. | American Alternative (Ad)Fresenius Medical in-pact with Coordination of National Institutes in MexicoJuly 3, 2025 | msn.comFSNUY Fresenius SE & Co. KGaA - Seeking AlphaJune 28, 2025 | seekingalpha.comFresenius: Healthy Portfolio AddJune 7, 2025 | seekingalpha.comFresenius SE price target raised to EUR 52 from EUR 43 at CitiJune 5, 2025 | msn.comThree Days Left Until Fresenius SE & Co. KGaA (ETR:FRE) Trades Ex-DividendMay 22, 2025 | finance.yahoo.comSee More Headlines FSNUY Stock Analysis - Frequently Asked Questions How have FSNUY shares performed this year? Fresenius SE & Co.'s stock was trading at $8.75 at the start of the year. Since then, FSNUY stock has increased by 36.9% and is now trading at $11.98. How were Fresenius SE & Co.'s earnings last quarter? Fresenius SE & Co. (OTCMKTS:FSNUY) released its quarterly earnings data on Wednesday, May, 7th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.01. The firm earned $5.92 billion during the quarter, compared to the consensus estimate of $5.41 billion. Fresenius SE & Co. had a net margin of 1.92% and a trailing twelve-month return on equity of 9.06%. How do I buy shares of Fresenius SE & Co.? Shares of FSNUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2025Ex-Dividend for 6/4 Dividend5/27/2025Record date for 6/4 Dividend5/28/2025Dividend Payable6/04/2025Today8/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryMedical Equipment Current SymbolOTCMKTS:FSNUY CIKN/A Webwww.fresenius.com Phone(496) 172-6080FaxN/AEmployees176,486Year Founded1912Profitability EPS (Trailing Twelve Months)$0.19 Trailing P/E Ratio63.06 Forward P/E Ratio15.16 P/E GrowthN/ANet Income$509.67 million Net Margins1.92% Pretax Margin7.17% Return on Equity9.06% Return on Assets4.17% Debt Debt-to-Equity Ratio0.50 Current Ratio1.43 Quick Ratio1.11 Sales & Book Value Annual Sales$23.63 billion Price / SalesN/A Cash Flow$1.28 per share Price / Cash Flow9.37 Book Value$9.83 per share Price / Book1.22Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.75 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (OTCMKTS:FSNUY) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fresenius SE & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fresenius SE & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.